Roszkowska Anna M, Spinella Rosaria, Calderone Alessandro, Sindoni Marianna, Wowra Bogumił H, Kozak Maciej, Sajak-Hydzik Katarzyna, Aliò Jorge
Ophthalmology Clinic, Department of Biomedical Sciences, University Hospital of Messina, Messina, Italy.
Ophthalmology Department, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland.
Front Ophthalmol (Lausanne). 2024 Jul 8;4:1408587. doi: 10.3389/fopht.2024.1408587. eCollection 2024.
Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.
神经营养性角膜炎或角膜病变（NK）是一种由三叉神经功能受损引起的角膜退行性疾病。这种情况可能导致持续性上皮缺损、角膜溃疡和穿孔。NK的诊断需要仔细调查与该疾病相关的任何眼部和全身状况以及眼表和角膜敏感性检查。过去，曾采用多种药物和手术方法治疗这种疾病，临床效果各异。西奈吉明是一种重组人神经生长因子（rh-NGF），可支持角膜再神经支配。不同的临床试验已证明局部使用西奈吉明治疗中度至重度神经营养性角膜炎患者的安全性和有效性。在本综述中，我们报告了自2017年和2018年分别获得欧洲药品管理局（EMA）和美国食品药品监督管理局（FDA）批准以来，关于使用西奈吉明治疗NK的临床结果的文献。
